Literature DB >> 8640766

Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol).

C Dumontet1, G E Duran, K A Steger, L Beketic-Oreskovic, B I Sikic.   

Abstract

A fluctuation analysis experiment was performed by exposing 15 expanded populations of MES-SA sarcoma cells to paclitaxel (Taxol) at a concentration of 10 nM for 7 days. The mutation rate was approximately 8 multiplied by 10(-7)/cell generation. ANOVA supports a stochastic cell survival mechanism of spontaneous mutation rather than induction of an adaptive response under these selection conditions. Surviving colonies were found in 12 populations, 9 of which had clones that remained resistant to paclitaxel after a 2-month period of propagation. Analysis of mdr1 gene expression by reverse transcription PCR demonstrated positive clones in 4 of the 9 populations with stable resistance. Accumulation of [(3)H]paclitaxel was decreased in these clones but not in the mdr1-negative clones compared with parental cells. A high degree of resistance to paclitaxel (36- to 93-fold) was selected by this single drug exposure in all 9 stably resistant mutants. Those with mdr1 activation demonstrated a broad cross-resistance to vinblastine, doxorubicin, and etoposide, whereas the other 6 mutants were cross-resistant only to the Vinca alkaloids. Because tubulins are the target molecules for paclitaxel cytotoxicity, we evaluated total tubulin content by immunoblotting and performed semiquantitative reverse transcription PCR analysis for expression of the alpha-tubulin isotypes B alpha 1, K alpha 1 and H alpha 44, the beta-tubulin isotypes M40, beta9, 5beta, beta2 and beta4, and gamma-tubulin. Total tubulin content was decreased significantly in one of the single-step mutants. All surviving clones, both resistant and sensitive to paclitaxel, displayed reduced expression of the 5beta and beta 4 beta-tubulin isotype transcripts in comparison with the parental cell line. These data suggest that stringent exposure to paclitaxel selected clones with reduced transcript levels of 5beta and beta4 beta-tubulin isotypes, but that these reduced levels were not directly involved in the resistance of the clones to paclitaxel. The results suggest an important role for non-multidrug-resistant mechanisms of resistance to paclitaxel. These mechanisms do not involve reduced drug accumulation and provide cross-resistance among both paclitaxel and tubulin depolymerizing agents.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8640766

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  Effects of Taxotere on invasive potential and multidrug resistance phenotype in pancreatic carcinoma cell line SUIT-2.

Authors:  B Liu; E Staren; T Iwamura; H Appert; J Howard
Journal:  World J Gastroenterol       Date:  2001-02       Impact factor: 5.742

Review 2.  The challenge of drug resistance in cancer treatment: a current overview.

Authors:  Michail Nikolaou; Athanasia Pavlopoulou; Alexandros G Georgakilas; Efthymios Kyrodimos
Journal:  Clin Exp Metastasis       Date:  2018-05-24       Impact factor: 5.150

Review 3.  Molecular pathways: regulation and therapeutic implications of multidrug resistance.

Authors:  Kevin G Chen; Branimir I Sikic
Journal:  Clin Cancer Res       Date:  2012-02-16       Impact factor: 12.531

4.  Determinants of paclitaxel uptake, accumulation and retention in solid tumors.

Authors:  S H Jang; M G Wientjes; J L Au
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

5.  Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics.

Authors:  A Gonçalves; D Braguer; K Kamath; L Martello; C Briand; S Horwitz; L Wilson; M A Jordan
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-18       Impact factor: 11.205

6.  Taxotere resistance in SUIT Taxotere resistance in pancreatic carcinoma cell line SUIT 2 and its sublines.

Authors:  B Liu; E Staren; T Iwamura; H Appert; J Howard
Journal:  World J Gastroenterol       Date:  2001-12       Impact factor: 5.742

7.  Molecular mechanisms of drug resistance in single-step and multi-step drug-selected cancer cells.

Authors:  Anna Maria Calcagno; Suresh V Ambudkar
Journal:  Methods Mol Biol       Date:  2010

8.  Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.

Authors:  Robert Chen; Joycelynne M Palmer; Peter Martin; Nicole Tsai; Young Kim; Bihong T Chen; Leslie Popplewell; Tanya Siddiqi; Sandra H Thomas; Michelle Mott; Firoozeh Sahebi; Saro Armenian; John Leonard; Auayporn Nademanee; Stephen J Forman
Journal:  Biol Blood Marrow Transplant       Date:  2015-07-26       Impact factor: 5.742

9.  Azaindole derivatives are inhibitors of microtubule dynamics, with anti-cancer and anti-angiogenic activities.

Authors:  Renaud Prudent; Émilie Vassal-Stermann; Chi-Hung Nguyen; Marjorie Mollaret; Jean Viallet; Agnès Desroches-Castan; Anne Martinez; Caroline Barette; Catherine Pillet; Glaucio Valdameri; Emmanuelle Soleilhac; Attilio Di Pietro; Jean-Jacques Feige; Marc Billaud; Jean-Claude Florent; Laurence Lafanechère
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

10.  Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents.

Authors:  M V Ramana Reddy; Muralidhar R Mallireddigari; Venkat R Pallela; Stephen C Cosenza; Vinay K Billa; Balaiah Akula; D R C Venkata Subbaiah; E Vijaya Bharathi; Amol Padgaonkar; Hua Lv; James M Gallo; E Premkumar Reddy
Journal:  J Med Chem       Date:  2013-06-25       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.